1 ANNEX, Regulation (EU) 2021/849

In forcesince 11 Mar 2021

In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:

(1)

the following entries are inserted:

Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M-factors and ATE | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘601-093-00-6 | 1,4-dimethylnaphthalene | 209-335-9 | 571-58-4 |

Acute Tox. 4

Asp. Tox. 1

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 3

H302

H304

H319

H400

H412

GHS07

GHS08

GHS09

Dgr

H302

H304

H319

H410

oral: ATE = 1300 mg/kg bw

M = 1’

‘601-094-00-1 |

1-isopropyl-4-methylbenzene;

p-cymene

202-796-7 | 99-87-6 |

Flam. Liq. 3

Acute Tox. 3

Asp. Tox. 1

Aquatic Chronic 2

H226

H331

H304

H411

GHS02

GHS06

GHS08

GHS09

Dgr

H226

H331

H304

H411

inhalation: ATE = 3 mg/l (vapours)’ |

‘601-095-00-7 |

p-mentha-1,3-diene; 1-isopropyl-4-methylcyclohexa-1,3-diene;

alpha-terpinene

202-795-1 | 99-86-5 |

Flam. Liq. 3

Acute Tox. 4

Skin Sens. 1

Asp. Tox. 1

Aquatic Chronic 2

H226

H302

H317

H304

H411

GHS02

GHS07

GHS08

GHS09

Dgr

H226

H302

H317

H304

H411

oral: ATE = 1680 mg/kg bw’ |

‘602-110-00-X | tetrafluoroethylene | 204-126-9 | 116-14-3 | Carc. 1B | H350 |

GHS08

Dgr

H350’ | | |

‘604-095-00-5 |

6,6'-di-tert-butyl-2,2'-methylenedi-p-cresol;

[DBMC]

204-327-1 | 119-47-1 | Repr. 1B | H360F |

GHS08

Dgr

H360F’ | | |

‘606-152-00-X | (5-chloro-2-methoxy-4-methyl-3-pyridyl)(4,5,6-trimethoxy-o-tolyl)methanone; pyriofenone | - | 688046-61-9 |

Carc. 2

Aquatic Chronic 1

H351

H410

GHS08

GHS09

Wng

H351

H410

M = 1’ |

‘607-747-00-7 | 2,2-dibromo-2-cyanoacetamide; [DBNPA] | 233-539-7 | 10222-01-2 |

Acute Tox. 2

Acute Tox. 3

STOT RE 1

Skin Irrit. 2

Eye Dam. 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H330

H301

H372 (respiratory tract) (inhalation)

H315

H318

H317

H400

H410

GHS06

GHS08

GHS05

GHS09

Dgr

H330

H301

H372 (respiratory tract) (inhalation)

H315

H318

H317

H410

inhalation: ATE = 0,24 mg/l (dusts or mists)

oral: ATE = 118 mg/kg bw

M = 1

M = 1’

‘607-748-00-2 |

[S-(Z,E)]-5-(1-hydroxy-2,6,6-trimethyl-4-oxocyclohex-2-en-1-yl)-3-methylpenta-2,4-dienoic acid;

S-abscisic acid

244-319-5 | 21293-29-8 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 1

M = 1’

‘607-749-00-8 | methyl salicylate | 204-317-7 | 119-36-8 |

Repr. 2

Acute Tox. 4

Skin Sens. 1B

Aquatic Chronic 3

H361d

H302

H317

H412

GHS07

GHS08

Wng

H361d

H302

H317

H412

oral: ATE = 890 mg/kg bw’ |

‘607-750-00-3 | citric acid | 201-069-1 | 77-92-9 |

Eye Irrit. 2

STOT SE 3

H319

H335

GHS07

Wng

H319

H335’

‘607-751-00-9 |

ethametsulfuron-methyl (ISO);

methyl 2-({[4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)benzoate

–

| 97780-06-8 |

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H319

H400

H410

GHS07

GHS09

Wng

H319

H410

M = 1000

M = 100’

‘607-752-00-4 |

trinexapac-ethyl (ISO);

ethyl 4-[cyclopropyl(hydroxy)methylene]-3,5-dioxocyclohexanecarboxylate

–

| 95266-40-3 |

STOT RE 2

Skin Sens. 1B

Aquatic Chronic 1

H373 (gastrointestinal tract)

H317

H410

GHS08

GHS07

GHS09

Wng

H373 (gastrointestinal tract)

H317

H410

M = 1’ |

‘607-753-00-X | (3aS,5S,6R,7aR,7bS,9aS,10R,12aS,12bS)-10-[(2S,3R,4R,5R)-3,4-dihydroxy-5,6-dimethylheptan-2-yl]-5,6-dihydroxy-7a,9a-dimethylhexadecahydro-3H-benzo[c]indeno[5,4-e]oxepin-3-one; 24-epibrassinolide | - | 78821-43-9 | Aquatic Chronic 4 | H413 | | H413’ | | |

‘607-754-00-5 | benzyl salicylate | 204-262-9 | 118-58-1 | Skin Sens. 1B | H317 |

GHS07

Wng

H317’ | | |

‘607-755-00-0 |

(RS)-1-{1-ethyl-4-[4-mesyl-3-(2-methoxyethoxy)-o-toluoyl]pyrazol-5-yloxy}ethyl methyl carbonate;

tolpyralate

–

| 1101132-67-5 |

Carc. 2

Repr. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H361fd

H373 (eye)

H400

H410

GHS08

GHS09

Wng

H351

H361fd

H373 (eye)

H410

M = 10

M = 100’

‘613-337-00-9 |

prothioconazole (ISO);

2-[2-(1-chlorocyclopropyl)-3-(2-chlorophenyl)-2-hydroxypropyl]-2,4-dihydro-3H-1,2,4-triazole-3-thione

–

| 178928-70-6 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 10

M = 1’

‘613-338-00-4 | azamethiphos (ISO); S-[(6-chloro-2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)methyl] O,O-dimethyl thiophosphate | 252-626-0 | 35575-96-3 |

Carc. 2

Acute Tox. 3

Acute Tox. 4

STOT SE 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H331

H302

H370 (nervous system)

H317

H400

H410

GHS06

GHS08

GHS09

Dgr

H351

H331

H302

H370 (nervous system)

H317

H410

inhalation: ATE = 0,5 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 1000

M = 1000’

‘613-339-00-X | 3-methylpyrazole | 215-925-7 | 1453-58-3 |

Repr. 1B

Acute Tox. 4

STOT RE 2

Skin Corr. 1

Eye Dam. 1

H360D

H302

H373 (lung)

H314

H318

GHS08

GHS07

GHS05

Dgr

H360D

H302

H373 (lung)

H314

oral: ATE = 500 mg/kg bw’ |

‘613-340-00-5 | clomazone (ISO); 2-(2-chlorobenzyl)-4,4-dimethyl-1,2-oxazolidin-3-one | - | 81777-89-1 |

Acute Tox. 4

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H400

H410

GHS07

GHS09

Wng

H332

H302

H410

inhalation: ATE = 4,85 mg/l (dusts or mists)

oral: ATE = 768 mg/kg bw

M = 1

M = 1’

‘614-030-00-2 | emamectin benzoate (ISO); (4"R)-4"-deoxy-4"-(methylamino) avermectin B1 benzoate | - | 155569-91-8 |

Acute Tox. 3

Acute Tox. 3

Acute Tox. 3

STOT SE 1

STOT RE 1

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H331

H311

H301

H370 (nervous system)

H372 (nervous system)

H318

H400

H410

GHS06

GHS05

GHS08

GHS09

Dgr

H331

H311

H301

H370 (nervous system)

H372 (nervous system)

H318

H410

inhalation:

ATE = 0,663

mg/l (dusts or mists)

dermal:

ATE = 300

mg/kg bw

oral: ATE =

60 mg/kg bw

STOT RE 1; H372: C ≥ 5 %; STOT RE 2; H373: 0,5 % ≤ C < 5 %

M = 10000

M = 10000’

‘616-234-00-7 | N-methoxy-N-[1-methyl-2-(2,4,6-trichlorophenyl)-ethyl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide; pydiflumetofen | - | 1228284-64-7 |

Carc. 2

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H351

H361f

H400

H410

GHS08

GHS09

Wng

H351

H361f

H410

M = 1

M = 1’

‘616-235-00-2 | N-{2-[[1,1'-bi(cyclopropyl)]-2-yl]phenyl}-3-(difluoromethyl)-1-methyl-1H-pyrazole-4-carboxamide; sedaxane | - | 874967-67-6 |

Carc. 2

Aquatic Acute 1

Aquatic Chronic 2

H351

H400

H411

GHS08

GHS09

Wng

H351

H410

M = 1’ |

(2)

the entries corresponding to index numbers 005-007-00-2; 005-008-00-8; 005-011-00-4; 005-011-01-1; 005-011-02-9; 006-069-00-3; 006-076-00-1; 015-113-00-0; 028-007-00-4; 029-002-00-X; 029-015-00-0; 029-016-00-6; 029-017-00-1; 029-018-00-7; 029-019-01-X; 029-020-00-8; 029-021-00-3; 029-022-00-9; 029-023-00-4; 601-029-00-7; 601-096-00-2; 603-024-00-5; 603-066-00-4; 603-098-00-9; 606-004-00-4; 607-421-00-4; 607-424-00-0; 607-434-00-5; 608-058-00-4; 612-067-00-9; 612-252-00-4; 613-048-00-8; 613-102-00-0; 613-111-00-X; 613-166-00-X; 613-208-00-7; 613-267-00-9; 613-282-00-0; 616-032-00-9; 616-106-00-0 and 616-113-00-9 are replaced by the following entries respectively:

Index No | Chemical Name | EC No | CAS No | Classification | Labelling | Specific Conc. Limits, M- factors and ATE | Notes

Hazard Class and Category Code(s) | Hazard statement Code(s) | Pictogram, Signal Word Code(s) | Hazard statement Code(s) | Suppl. Hazard statement Code(s)

‘005-007-00-2 |

boric acid [1]

boric acid [2]

233-139-2 [1]

234-343-4 [2]

10043-35-3 [1]

11113-50-1 [2]

Repr. 1B | H360FD |

GHS08

Dgr

H360FD’ | | |

‘005-008-00-8 | diboron trioxide | 215-125-8 | 1303-86-2 | Repr. 1B | H360FD |

GHS08

Dgr

H360FD’ | | |

‘005-011-00-4 |

tetraboron disodium heptaoxide, hydrate; [1]

disodium tetraborate, anhydrous; [2]

orthoboric acid, sodium salt [3]

disodium tetraborate decahydrate [4]

disodium tetraborate pentahydrate [5]

235-541-3 [1]

215-540-4 [2]

237-560-2 [3]

215-540-4 [4]

215-540-4 [5]

12267-73-1 [1]

1330-43-4 [2]

13840-56-7 [3]

1303-96-4 [4]

12179-04-3 [5]

Repr. 1B | H360FD |

GHS08

Dgr

H360FD’ | | |

‘006-069-00-3 |

thiophanate-methyl (ISO);

dimethyl (1,2-phenylenedicarbamothioyl)biscarbamate;

dimethyl 4,4′-(o-phenylene)bis(3-thioallophanate)

245-740-7 | 23564-05-8 |

Carc. 2

Muta. 2

Acute Tox. 4

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H341

H332

H317

H400

H410

GHS08

GHS07

GHS09

Wng

H351

H341

H332

H317

H410

inhalation: ATE = 1,7 mg/l

(dusts and mists)

M = 10

M = 10’

‘006-076-00-1 | mancozeb (ISO); manganese ethylenebis(dithiocarbamate) (polymeric) complex with zinc salt | - | 8018-01-7 |

Carc. 2

Repr. 1B

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H351

H360D

H373 (thyroid, nervous system)

H317

H400

H410

GHS08

GHS07

GHS09

Dgr

H351

H360D

H373 (thyroid, nervous system)

H317

H410

M = 10

M = 10’

‘015-113-00-0 |

tolclofos-methyl (ISO);

O-(2,6-dichloro-p-tolyl) O,O-dimethyl thiophosphate

260-515-3 | 57018-04-9 |

Skin Sens. 1B

Aquatic Acute 1

Aquatic Chronic 1

H317

H400

H410

GHS07

GHS09

Wng

H317

H410

M = 1

M = 1’

‘028-007-00-4 |

trinickel disulfide;

nickel subsulfide; [1]

heazlewoodite [2]

234-829-6 [1]

–

[2]

12035-72-2 [1]

12035-71-1 [2]

Carc. 1A

Muta. 2

Acute Tox. 3

STOT RE 1

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H350i

H341

H331

H372**

H317

H400

H410

GHS08

GHS06

GHS09

Dgr

H350i

H341

H331

H372**

H317

H410

inhalation:

ATE = 0,92 mg/l

(dusts or mists)’

‘029-002-00-X |

dicopper oxide;

copper (I) oxide

215-270-7 | 1317-39-1 |

Acute Tox. 4

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H302

H318

H410

inhalation: ATE = 3,34 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 100

M = 10’

‘029-015-00-0 | copper thiocyanate | 214-183-1 | 1111-67-7 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | EUH032 |

M = 10

M = 10’

‘029-016-00-6 | copper(II) oxide | 215-269-1 | 1317-38-0 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 100

M = 10’

‘029-017-00-1 | dicopper chloride trihydroxide | 215-572-9 | 1332-65-6 |

Acute Tox. 4

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H332

H301

H400

H410

GHS06

GHS09

Dgr

H332

H301

H410

inhalation: ATE = 2,83 mg/l (dusts or mists)

oral: ATE = 299 mg/kg bw

M = 10

M = 10’

‘029-018-00-7 |

tetracopper hexahydroxide sulphate; [1]

tetracopper hexahydroxide sulphate hydrate [2]

215-582-3 [1]

215-582-3 [2]

1333-22-8 [1]

12527-76-3 [2]

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H302

H400

H410

GHS07

GHS09

Wng

H302

H410

oral: ATE = 500 mg/kg bw

M = 10

M = 10’

‘029-019-01-X | copper flakes (coated with aliphatic acid) | - | - |

Acute Tox. 3

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H331

H302

H319

H400

H410

GHS06

GHS09

Dgr

H331

H302

H319

H410

inhalation: ATE = 0,733 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 10

M = 10’

‘029-020-00-8 | copper(II) carbonate—copper(II) hydroxide (1:1) | 235-113-6 | 12069-69-1 |

Acute Tox. 4

Acute Tox. 4

Eye Irrit. 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H319

H400

H410

GHS07

GHS09

Wng

H332

H302

H319

H410

inhalation: ATE = 1,2 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 10

M = 10’

‘029-021-00-3 |

copper dihydroxide;

copper(II) hydroxide

243-815-9 | 20427-59-2 |

Acute Tox. 2

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H330

H302

H318

H400

H410

GHS06

GHS05

GHS09

Dgr

H330

H302

H318

H410

inhalation: ATE = 0,47 mg/l (dusts or mists)

oral: ATE = 500 mg/kg bw

M = 10

M = 10’

‘029-022-00-9 |

bordeaux mixture;

reaction products of copper sulphate with calcium dihydroxide

–

| 8011-63-0 |

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H332

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H332

H318

H410

inhalation: ATE = 1,97 mg/l (dusts or mists)

M = 10

M = 1’

‘029-023-00-4 | copper sulphate pentahydrate | 231-847-6 | 7758-99-8 |

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H302

H318

H410

oral: ATE = 481 mg/kg bw

M = 10

M = 1’

‘601-029-00-7 |

dipentene;

limonene [1]

(S)-p-mentha-1,8-diene; l-limonene [2]

trans-1-methyl-4-(1-methylvinyl)cyclohexene; [3]

(±)-1-methyl-4-(1-methylvinyl)cyclohexene [4]

205-341-0 [1]

227-815-6 [2]

229-977-3 [3]

231-732-0 [4]

138-86-3 [1]

5989-54-8 [2]

6876-12-6 [3]

7705-14-8 [4]

Flam. Liq. 3

Skin Irrit. 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H226

H315

H317

H400

H410

GHS02

GHS07

GHS09

Wng

H226

H315

H317

H410

C’

‘601-096-00-2 |

(R)-p-mentha-1,8-diene;

d-limonene

227-813-5 | 5989-27-5 |

Flam. Liq. 3

Skin Irrit. 2

Skin Sens. 1B

Asp. Tox. 1

Aquatic Acute 1

Aquatic Chronic 3

H226

H315

H317

H304

H400

H412

GHS02

GHS07

GHS08

GHS09

Dgr

H226

H315

H317

H304

H410

M = 1’ |

‘603-024-00-5 | 1,4-dioxane | 204-661-8 | 123-91-1 |

Flam. Liq. 2

Carc. 1B

STOT SE 3

Eye Irrit. 2

H225

H350

H335

H319

GHS02

GHS08

GHS07

Dgr

H225

H350

H335

H319

EUH019

EUH066

D’

‘603-066-00-4 | 7-oxa-3-oxiranylbicyclo[4.1.0]heptane; 1,2-epoxy-4-epoxyethylcyclohexane; 4-vinylcyclohexene diepoxide | 203-437-7 | 106-87-6 |

Carc. 1B

Muta. 2

Repr. 1B

Acute Tox. 3

Acute Tox. 4

H350

H341

H360F

H331

H302

GHS08

GHS06

Dgr

H350

H341

H360F

H331

H302

inhalation: ATE = 0,5 mg/l (dusts or mists)

oral: ATE = 1847 mg/kg bw’

‘603-098-00-9 | 2-phenoxyethanol | 204-589-7 | 122-99-6 |

Acute Tox. 4

STOT SE 3

Eye Dam. 1

H302

H335

H318

GHS05

GHS07

Dgr

H302

H335

H318

oral:

ATE = 1394 mg/kg bw’

‘606-004-00-4 | 4-methylpentan-2-one; isobutyl methyl ketone | 203-550-1 | 108-10-1 |

Flam. Liq. 2

Carc. 2

Acute Tox. 4

STOT SE 3

Eye Irrit. 2

H225

H351

H332

H336

H319

GHS02

GHS07

GHS08

Dgr

H225

H351

H332

H336

H319

EUH066 | inhalation: ATE = 11 mg/l (vapours)’ |

‘607-421-00-4 |

cypermethrin (ISO);

α-cyano-3-phenoxybenzyl 3-(2,2-dichlorovinyl)-2,2-dimethylcyclopropanecarboxylate; cypermethrin cis/trans +/- 40/60

257-842-9 | 52315-07-8 |

Acute Tox. 4

Acute Tox. 4

STOT SE 3

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H332

H302

H335

H373 (nervous system)

H400

H410

GHS07

GHS08

GHS09

Wng

H332

H302

H335

H373 (nervous system)

H410

oral; ATE = 500 mg/kg bw

inhalation; ATE = 3,3 mg/l (dusts or mists)

M = 100000

M = 100000’

‘607-424-00-0 | trifloxystrobin (ISO); methyl (E)-methoxyimino-{(E)-α-[1-(α,α,α-trifluoro-m-tolyl)ethylideneaminooxy]-o-tolyl}acetate | - | 141517-21-7 |

Lact.

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H362

H317

H400

H410

GHS07

GHS09

Wng

H362

H317

H410

M = 100

M = 10’

‘607-434-00-5 |

mecoprop-P (ISO) [1] and its salts;

(R)-2-(4-chloro-2-methylphenoxy)propionic acid [1] and its salts

240-539-0 [1] | 16484-77-8 [1] |

Acute Tox. 4

Eye Dam. 1

Aquatic Acute 1

Aquatic Chronic 1

H302

H318

H400

H410

GHS07

GHS05

GHS09

Dgr

H302

H318

H410

oral: ATE = 431 mg/kg bw

M = 10

M = 10’

‘608-058-00-4 |

esfenvalerate (ISO);

(S)-α-cyano-3-phenoxybenzyl-(S)-2-(4-chlorophenyl)-3-methylbutyrate

–

| 66230-04-4 |

Acute Tox. 3

Acute Tox. 3

STOT SE 1

STOT RE 2

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H331

H301

H370 (nervous system)

H373

H317

H400

H410

GHS06

GHS08

GHS09

Dgr

H331

H301

H370 (nervous system)

H373

H317

H410

oral; ATE = 88,5 mg/kg bw

inhalation; ATE = 0,53 mg/l (dusts or mists)

M = 10000

M = 10000’

‘612-067-00-9 | 3-aminomethyl-3,5,5-trimethylcyclohexylamine | 220-666-8 | 2855-13-2 |

Acute Tox. 4

Skin Corr. 1B

Eye Dam. 1

Skin Sens. 1A

H302

H314

H318

H317

GHS05

GHS07

Dgr

H302

H314

H317

oral: ATE = 1030 mg/kg bw

Skin Sens. 1A; H317: C ≥ 0,001 %’

‘612-252-00-4 |

imidacloprid (ISO);

(E)-1-(6-chloro-3-pyridylmethyl)-N-nitroimidazolidin-2-ylideneamine;

(2E)-1-[(6-chloropyridin-3-yl) methyl]-N-nitroimidazolidin-2-imine

428-040-8 | 138261-41-3 |

Acute Tox. 3

Aquatic Acute 1

Aquatic Chronic 1

H301

H400

H410

GHS06

GHS09

Dgr

H301

H410

oral: ATE = 131 mg/kg bw

M = 100

M = 1000’

‘613-048-00-8 | carbendazim (ISO); methyl benzimidazol-2-ylcarbamate | 234-232-0 | 10605-21-7 |

Muta. 1B

Repr. 1B

Skin Sens. 1

Aquatic Acute 1

Aquatic Chronic 1

H340

H360FD

H317

H400

H410

GHS07

GHS08

GHS09

Dgr

H340

H360FD

H317

H410

M = 10

M = 10’

‘613-102-00-0 | dimethomorph (ISO); (E,Z)-4-(3-(4-chlorophenyl)-3-(3,4-dimethoxyphenyl)acryloyl)morpholine | 404-200-2 | 110488-70-5 |

Repr. 1B

Aquatic Chronic 2

H360F

H411

GHS08

GHS09

Dgr

H360F

H411’

‘613-111-00-X | 1,2,4-triazole | 206-022-9 | 288-88-0 |

Repr. 1B

Acute Tox. 4

Eye Irrit. 2

H360FD

H302

H319

GHS08

GHS07

Dgr

H360FD

H302

H319

oral: ATE = 1320 mg/kg bw’ |

‘613-166-00-X |

flumioxazin (ISO);

N-(7-fluoro-3,4-dihydro-3-oxo-4-prop-2-ynyl-2H-1,4-benzoxazin-6-yl)cyclohex-1-ene-1,2-dicarboximide

–

| 103361-09-7 |

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GHS09

Wng

H361d

H410

M = 1000

M = 1000’

‘613-208-00-7 |

imazamox (ISO);

(RS)-2-(4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-yl)-5-methoxymethylnicotinic acid

–

| 114311-32-9 |

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GHS09

Wng

H361d

H410

M = 10

M = 10’

‘613-267-00-9 |

thiamethoxam (ISO);

3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine

428-650-4 | 153719-23-4 |

Repr. 2

Acute Tox. 4

Aquatic Acute 1

Aquatic Chronic 1

H361fd

H302

H400

H410

GHS07

GHS08

GHS09

Wng

H361fd

H302

H410

oral: ATE = 780 mg/kg bw

M = 10

M = 10’

‘613-282-00-0 |

triticonazole (ISO);

(RS)-(E)-5-(4-chlorobenzylidene)-2,2-dimethyl-1-(1H-1,2,4-triazol-1-methyl)cyclopentanol

–

| 138182-18-0 |

Repr. 2

STOT RE 2

Aquatic Acute 1

Aquatic Chronic 1

H361f

H373

H400

H410

GHS08

GHS09

Wng

H361f

H373

H410

M = 1

M = 1’

‘616-032-00-9 |

diflufenican (ISO);

N-(2,4-difluorophenyl)-2-[3-(trifluoromethyl)phenoxy]-3-pyridinecarboxamide; 2′,4′-difluoro-2-(α,α,α-trifluoro-m-tolyloxy) nicotinanilide

–

| 83164-33-4 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 10000

M = 1000’

‘616-106-00-0 | phenmedipham (ISO); methyl 3-(3-methylcarbaniloyloxy)carbanilate | 237-199-0 | 13684-63-4 |

Aquatic Acute 1

Aquatic Chronic 1

H400

H410

GHS09

Wng

H410 | |

M = 10

M = 10’

‘616-113-00-9 |

desmedipham (ISO);

ethyl 3-phenylcarbamoyloxyphenylcarbamate

237-198-5 | 13684-56-5 |

Repr. 2

Aquatic Acute 1

Aquatic Chronic 1

H361d

H400

H410

GHS08

GHS09

Wng

H361d

H410

M = 10

M = 10’

(3)

the entry corresponding to index number 015-192-00-1 is deleted.